Investigating levothyroxine drug release on synthesized nanocomposite containing magnetic cores covered with alginate polymer and metal-organic framework

Subject Areas : phytochemistry

Zaynab Madadi ¹ , Fadaeian Manochehr ² , Mohammad Ali Ghasemzade ³

1 - MSc, Department of Chemistry, Faculty of Basic Sciences, Qom Branch, Islamic Azad University, Qom, Iran
2 - Assistant Professor, Qom Branch, Islamic Azad University, Qom, Iran
3 - Associate Professor, Qom Branch, Islamic Azad University, Qom, Iran

Received: 2022-07-05 Accepted : 2022-09-11 Published : 2022-09-23

Keywords:  Metal-organic framework, Drug delivery-loading-release-levothyroxine, nanocomposite, Magnetic cores, Alginate polymer,

Abstract :

Objectives: Levothyroxine drug is used to treat thyroid diseases, which is one of the most common chronic diseases in the world, and considering that levothyroxine is a hydrophobic drug with low solubility and low stability, it requires an advanced drug delivery system. Among the targeted drug delivery systems, magnetically modified porous carriers have a high capacity to store drugs due to the presence of side groups, the adaptability of its porosity, and release it over a long period of time and instead of spreading throughout the body, it affects only the desired cell. he does.Materials and methods: The present research deals with preparing and identifying the metal-organic framework and investigating its performance in levothyroxine drug loading and release. First, MnCuFe2O4 nanoparticles were synthesized and covered by alginate polysaccharide. After that, the metal-organic framework 66-UiO was placed on it and the three-layer composite MnCuFe2O4@Alginate@UiO-66 was made.Findings: loading and release of levothyroxine drug on the synthesized nanocarrier was investigated at pH 7.4. The fabricated nanocomposite was examined by various methods such as SEM, EDX, FT-IR, BET. Nanocomposite was made with cheap and biodegradable raw materials such as alginate using an easy method with targeted drug delivery and magnetic strength.Conclusions: This nanocomposite with 87% loading capacity and 73% levothyroxine release can be used as a new and targeted drug delivery system. 

References:

1. Kaparissides C, Alexandridou S, Kotti K & Chaitidou S. Recent Advances in Novel Drug Delivery Systems. Nano. 2006; 2: 1-11.


2. Zhu Q-L & Xu Q. Metal–Organic Framework Composites. Chemical Society Revi. 2014; 43: 5468-5512.


3. Vallet-Regi M, Ramila A, Del Real & RP, Perez-Pariente J. A New Property of MCM-41: Drug Delivery System. Mater. 2001; 13: 308-311.


4. Torcilin VP. Nanoparticulates as drug carriers. Imperial College Press. 2006.


5. Varadan VK, Chen L & Xie J. Nanomedicine: design and applications of magnetic nanomaterials, nanosensors and nanosystems. Wiley. 2008.


6. Montha W, Maneeprakorn W, Buatong N, Tang IM & Pon-On W. Synthesis of Doxorubicin-PLGA Loaded Chitosan Stabilized (Mn, Zn) Fe2O4 Nanoparticles: Biological Activity and pH-Responsive Drug Release. Materials Science and Engineering. 2015; 59: 235-240.


7. Eiseh O, Gunn JW & Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Advanced Drug Delivery Reviews. 2010; 62.


8. Rowley JA, Madlambayan G & Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials. 1999; 20(1): 45-53.


9. Sun C, Lee JSH & Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews. 2008; 60.


10. Svensson J & et al. Levothyroxine Treatment Reduces Thyroid Size in Children and Adolescents with Chronic Autoimmune Thyroiditis. The Journal of Clinical Endocrinology & Metabolism. 2005; 1729: 91-1734.


11. Kannapiran N & et al. Effect of MnCuFe2O4 content on magnetic and dielectric properties of poly (O- Phenylenediamine)/MnCuFe2O4 nanocomposites. The Journal of Magnetism and Magnetic Materials. 2016; 401(1): 345-353.


12. Lede TI & et al. Thermal stability of synthetic thyroid hormone l-thyroxine and
    l-thyroxine sodium salt hydrate both pure and in pharmaceutical formulations. Pharm. Biomed. Anal. 2016; 125: 33-40.